KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) EBITDA (2016 - 2025)

Fulgent Genetics' EBITDA history spans 11 years, with the latest figure at $40.2 million for Q4 2025.

  • For Q4 2025, EBITDA rose 348.86% year-over-year to $40.2 million; the TTM value through Dec 2025 reached -$14.7 million, up 80.11%, while the annual FY2025 figure was -$14.7 million, 80.11% up from the prior year.
  • EBITDA for Q4 2025 was $40.2 million at Fulgent Genetics, up from -$15.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $266.9 million in Q1 2021 and bottomed at -$151.1 million in Q4 2023.
  • The 5-year median for EBITDA is -$15.7 million (2024), against an average of $28.5 million.
  • The largest annual shift saw EBITDA surged 14045.77% in 2021 before it plummeted 8080.84% in 2024.
  • A 5-year view of EBITDA shows it stood at $150.9 million in 2021, then tumbled by 124.23% to -$36.6 million in 2022, then crashed by 313.44% to -$151.1 million in 2023, then skyrocketed by 89.32% to -$16.1 million in 2024, then surged by 348.86% to $40.2 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's EBITDA are $40.2 million (Q4 2025), -$15.4 million (Q3 2025), and -$19.7 million (Q2 2025).